The Knee
Volume 12, Issue 1 , Pages 57-62 , January 2005

Intra-articular hylan G-F 20 (Synvisc®) in the management of patellofemoral osteoarthritis of the knee (POAK)

  • Shane Clarke

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +44-117-928-7263; fax: +44-117-928-7236.
    • Rheumatology Unit, University Department of Medicine, Bristol Royal Infirmary, Bristol BS2 8HW, UK
    • ,
  • Vanessa Lock

      Affiliations

    • Rheumatology Unit, University Department of Medicine, Bristol Royal Infirmary, Bristol BS2 8HW, UK
    • ,
  • John Duddy

      Affiliations

    • Rheumatology Unit, University Department of Medicine, Bristol Royal Infirmary, Bristol BS2 8HW, UK
    • ,
  • Mohammed Sharif

      Affiliations

    • Rheumatology Unit, University Department of Medicine, Bristol Royal Infirmary, Bristol BS2 8HW, UK
    • ,
  • John H. Newman

      Affiliations

    • Department of Orthopaedic Surgery, Bristol Royal Infirmary, Bristol BS2 8HW, UK
    • ,
  • John R. Kirwan

      Affiliations

    • Rheumatology Unit, University Department of Medicine, Bristol Royal Infirmary, Bristol BS2 8HW, UK

Received 1 November 2003 ,Revised 5 February 2004 ,Accepted 14 March 2004.

References 

  1. Cooper C, McAlindon T, Snow S, Vines K, Young P, Kirwan J, et al.  Mechanical and constitutional risk factors for symptomatic knee osteoarthritis: differences between medial tibiofemoral and patellofemoral disease. J. Rheumatol. 1994;21:307–313
  2. Davies AP, Glasgow MM. Imaging in osteoarthritis: a guide to requesting plain X-rays of the degenerate knee. Knee. 2000;7:139–143
  3. Dahl LB, Dahl IM, Engstrom-Laurent A, Granath K. Concentration and molecular weight of sodium hyaluronate in synovial fluid from patients with rheumatoid arthritis and other arthropathies. Ann. Rheum. Dis. 1985;44:817–822
  4. Kirwan J. Is there a place for intra-articular hyaluronate in osteoarthritis of the knee?. Knee. 2001 (29-1);8:93–101
  5. Raynauld JP, Torrance GW, Band PA, Goldsmith CH, Tugwell P, Walker V, et al.  in collaboration with the Canadian Knee OA Study Group   A prospective, randomized, pragmatic, health outcomes trial evaluating the incorporation of hylan G-F 20 into the treatment paradigm for patients with knee osteoarthritis (Part 1 of 2): clinical results. Osteoarthr. Cartil. 2002;10:506–517
  6. Balazs EA, Denlinger JL. Viscosupplementation: a new concept in the treatment of osteoarthritis. J. Rheumatol. 1993 (1-1);20(s39):3–9
  7. Bellamy N, Buchanan WW, Goldsmith CH, Campbell J, Stitt LW. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol. 1988;15:1833–1840
  8. Dawson J, Fitzpatrick R, Murray D, Carr A. Questionnaire on the perceptions of patients about total knee replacement. J. Bone Joint Surg. Br. 1998;80:63–69
  9. Henderson EB, Smith EC, Pegley F, Blake DR. Intra-articular injections of 750 kD hyaluronan in the treatment of osteoarthritis: a randomised single centre double-blind placebo-controlled trial of 91 patients demonstrating lack of efficacy. Ann. Rheum. Dis. 1994;53:529–534
  10. Puttick MP, Wade JP, Chalmers A, Connell DG, Rangno KK. Acute local reactions after intraarticular hylan for osteoarthritis of the knee. J. Rheumatol. 1995;22:1311–1314
  11. Bernardeau C, Bucki B, Liote F. Acute arthritis after intra-articular hyaluronate injection: onset of effusions without crystal. Ann. Rheum. Dis. 2001;60:518–520

PII: S0968-0160(04)00076-6

doi: 10.1016/j.knee.2004.03.002

The Knee
Volume 12, Issue 1 , Pages 57-62 , January 2005

Article Tools

* Image Usage & Resolution